IRON
Disc Medicine, Inc.
$74.78
+4.62
(+6.58%)
Mkt Cap
2.86B
Volume
1,904,001
52W Range
40-99.5
Sector
Healthcare
Beta
2.10
EPS (TTM)
-6.64
P/E Ratio
-13.21
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (212.18M) | (109.36M) | (76.43M) | (46.83M) | (35.97M) | (40.84M) |
| EPS | -6.01 | -3.96 | -3.42 | -45.05 | -44.88 | -27.02 |
| Free Cash Flow | (181.33M) | (94.43M) | (73.55M) | (42.40M) | (27.60M) | (32.73M) |
| FCF / Share | -5.14 | -3.42 | -3.30 | -40.79 | -34.44 | -21.65 |
| Operating CF | (180.39M) | (93.93M) | (73.46M) | (42.25M) | (27.53M) | (32.71M) |
| Total Assets | 806.88M | 496.77M | 368.00M | 200.21M | 92.41M | 8.32M |
| Total Debt | 1.86M | 30.00M | 2.10M | 1.33M | 7.06M | 21.64M |
| Cash & Equiv | 91.14M | 192.43M | 360.38M | 194.61M | 88.04M | 4.50M |
| Book Value | 739.83M | 443.59M | 345.12M | 176.60M | (64.20M) | (21.86M) |
| Return on Equity | -0.29 | -0.25 | -0.22 | -0.27 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (63.50M) | (60.53M) | (62.32M) | (55.25M) | (34.09M) | (29.46M) | (26.60M) | (26.35M) | (26.95M) | (23.58M) | (14.12M) | (15.95M) |
| EPS | -1.65 | -1.64 | -1.77 | -1.58 | -1.02 | -0.98 | -0.89 | -1.03 | -1.09 | -1.00 | -0.58 | -0.74 |
| Free Cash Flow | (62.24M) | (43.32M) | (47.83M) | (47.95M) | (42.23M) | (28.02M) | (17.35M) | (15.39M) | (33.67M) | (17.80M) | (7.52M) | (12.74M) |
| FCF / Share | -1.62 | -1.23 | -1.36 | -1.37 | -1.27 | -0.94 | -0.58 | -0.60 | -1.36 | -0.76 | -0.31 | -0.59 |
| Operating CF | (62.24M) | (43.30M) | (47.80M) | (47.92M) | (41.38M) | (27.57M) | (17.36M) | (15.39M) | (33.60M) | (17.80M) | (7.48M) | (12.72M) |
| Total Assets | 750.21M | 806.88M | 630.46M | 665.06M | 709.27M | 496.77M | 495.14M | 510.22M | 354.18M | 368.00M | 376.50M | 384.17M |
| Total Debt | 31.06M | 1.86M | 30.98M | 30.92M | 30.64M | 30.00M | 1.79M | 1.84M | 2.03M | 2.10M | 1.96M | 2.09M |
| Cash & Equiv | 88.91M | 91.14M | 140.66M | 127.34M | 122.67M | 192.43M | 192.64M | 280.66M | 342.62M | 360.38M | 370.54M | 377.60M |
| Book Value | 688.43M | 739.83M | 573.39M | 614.16M | 660.36M | 443.59M | 467.96M | 488.83M | 338.07M | 345.12M | 358.97M | 371.22M |
| Return on Equity | -0.09 | -0.08 | -0.11 | -0.09 | -0.05 | -0.07 | -0.06 | -0.05 | -0.08 | -0.07 | -0.04 | -0.04 |
IRON News
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
ROSEN, LEADING INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights